Pancreatic islet transplantation in the treatment of diabetes mellitus

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 15, Issue 2, 2001, Pages 241-264

  Shapiro, A M James ^a   Ryan, Edmond A ^a   Lakey, Jonathan R T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Collagenase; Complications; Diabetes; Immunosuppres sion; Islet; Isolation; Pancreas

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; BINDING PROTEIN; BREQUINAR; CALCINEURIN INHIBITOR; CASPASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EVEROLIMUS; FINGOLIMOD; GLUCOCORTICOID; GLUCOSE; HEMOGLOBIN A1C; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; MALONONITRILE; MIZORIBINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAXIFYLLINE; OKT 3; RAPAMMUNE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOLOGY; DIABETES MELLITUS; DONOR; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN PUMP; INSULIN RESISTANCE; ISOLATED PANCREAS ISLET; ISOLATION PROCEDURE; LYMPHOMA; NEPHROTOXICITY; PANCREAS ISLET; PANCREAS ISLET DISEASE; PANCREAS ISLET TRANSPLANTATION; POSTOPERATIVE COMPLICATION; REVIEW; RISK; RISK BENEFIT ANALYSIS; STEM CELL; TREATMENT OUTCOME; XENOTRANSPLANTATION;

EID: 0034897746     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2001.0138     Document Type: Article

References (115)

1. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the U.S. population aged 20-74 years
2. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010
3. Type 2 diabetes in children. Exemplifies the growing problem of chronic diseases
4. Diabetes: Exploding type II
5. How many people in the U.S. have IDDM?
6. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications
7. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes
8. Predicting type I diabetes
9. Cell-mediated immune response to beta casein in recent-onset insulin-dependent diabetes: Implications for disease pathogenesis
10. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus
11. Unraveling the genetics of insulin-dependent type IA diabetes: The search must go on
12. Genetic analysis of type I diabetes using whole genome approaches
13. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus
14. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-IB gene
15. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus
16. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group
17. Subcutaneous glucose concentration in humans: Real estimation and continuous monitoring
18. Spectroscopic and clinical aspects of noninvasive glucose measurements
19. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy
20. Pancreatic transplantation after thirty years: Still room for improvement
21. Pancreas transplantation in humans
22. Position statement: Pancreas transplantation for patients with diabetes mellitus
23. Pancreas transplants: For whom?
24. Vascularised pancreas transplantation
25. Do retrospective and prospective quality of life assessments differ for pancreas-kidney transplant recipients?
26. Quality of life after pancreas transplantation: A review
27. Long-term quality of life after kidney and simultaneous pancreas-kidney transplantation
28. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type 1 diabetes and autonomic neuropathy
29. Simultaneous pancreas/kidney transplantation - A comparison of enteric and bladder drainage of exocrine pancreatic secretions
30. Comparison of pancreas transplantation with portal venous and enteric exocrine drainage to the standard technique utilizing bladder drainage of exocrine secretions
31. Indications of enteric conversion after pancreas transplantation with bladder drainage
32. Hepatic insulin resistance after pancreas transplantation in type 1 diabetes
33. Normalization of insulin sensitivity and glucose homeostasis in type I diabetic pancreas transplant recipients: A 48-month cross-sectional study - A clinical research center study
34. Pretransplant portal venous administration of donor antigen and portal venous allograft drainage synergistically prolong rat cardiac allograft survival
35. Patterns of acute rejection in portal-enteric versus systemic-bladder pancreas-kidney transplantation
36. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy
37. Notes on diabetes treated with extract and by grafts of sheep's pancreas
38. Weitere Mitteilungen über den Diabetes mellitus nach Extirpation des Pankreas
39. Extract from Banting's Notebook 2am October 31st
40. Improved survival of intraportal pancreatic islet cell allografts in patients with type-I diabetes mellitus by refined peritransplant management
41. Long-term metabolic results after pancreatic resection for severe chronic pancreatitis
42. Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis
43. Islet transplantation for patients with type I diabetes: Results, research priorities, and reasons for optimism
44. Incompatibility between human blood and isolated islets of Langerhans: A finding with implications for clinical intraportal islet transplantation?
45. Cell loss in isolated human islets occurs by apoptosis
46. Development of diagnostic markers for islet allograft rejection
47. Experimental pancreas allograft rejection: Correlation between histologic and function rejection and the efficacy of antirejection therapy
48. Detrimental effect of prednisone on canine islet autograft function
49. Acceleration of chronic failure of intrahepatic canine islet autografts by a short course of prednisone
50. Diabetogenic synergism in canine islet autografts from cyclosporine and steroids in combination
51. Post-transplant diabetes: Incidence, relationship to choice of immunosuppressive drugs, and treatment protocol
52. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group
53. Rapamycin (AY-22,989), a new antifungal antibiotic. II: Fermentation, isolation and characterization
54. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related
55. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients
56. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group
57. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group
58. Cyclosporin A, FK506, rapamycin: The use of a quantitative analytic tool to discriminate immunosuppressive drug interactions
59. Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse
60. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat
61. Sirolimus-tacrolimus combination immunosuppression
62. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis
63. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group
64. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation
65. Immunosuppression in the post-adaptation period
66. Long-term complications of diabetes mellitus
67. Islet transplantation in seven patients with type I diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
68. Portal vein thrombosis after transplantation of partially purified pancreatic islets in a combined human liver/islet allograft
69. Portal hypertension, hepatic infarction, and liver failure complicating pancreatic islet autotransplantation
70. Metabolic strategies to predict and improve intrahepatic islet graft function
71. Reduction of insulin resistance by combined kidney-pancreas transplantation in type I (insulin-dependent) diabetic patients
72. Evaluation of a purified enzyme blend for the recovery and function of canine pancreatic islets
73. Improved human islet isolation using a new enzyme blend, liberase
74. The optimization of large-scale density gradient isolation of human islets
75. The use of ficoll in the preparation of viable islets of Langerhans from the rat pancreas
76. Islet purification using Euro-Ficoll gradients
77. The use of ficoll in the separation of viable islets of Langerhans from the rat pancreas
78. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator
79. Variables in organ donors that affect the recovery of human islets of Langerhans
80. In vitro cultivation of human islets from expanded ductal tissue
81. Sensitization to HLA antigens in islet recipients with failing transplants
82. Isolated human islets trigger an instant blood mediated inflammatory reaction: Implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes
83. Suppression of acute rejection prevents graft arteriosclerosis after allogeneic aorta transplantation in the rat
84. Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model
85. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study
86. Impaired vibratory perception and diabetic foot ulceration
87. Semmes-Weinstein monofilaments: A simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration
88. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154
89. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
90. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
91. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
92. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment
93. Evidence that apoptosis activated T cells occurs in spontaneous tolerance of liver allografts and is blocked by manipulations which break tolerance
94. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: Implications for tolerance induction
95. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism
96. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: Absence of graft-versus-host disease, induction of skin allograft, tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice
97. Long-term functional islet mass and metabolic function after xenoislet transplantation in primates
98. Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin
99. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: Absence of chronic allograft nephropathy
100. Simultaneous pancreas-kidney transplantation from live donors
101. Living related donor pancreas and pancreas-kidney transplantation
102. Living versus cadaver donor pancreas transplants
103. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans
104. Comparison of harvesting methods for islet transplantation
105. Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters
106. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue
107. Glucose-dependent insulin release from genetically engineered K cells
108. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice
109. Infection of nonhuman primate cells by pig endogenous retrovirus
110. Infection of human cells by an endogenous retrovirus of pigs
111. Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice
112. Life supporting function for over one month of a transgenic porcine heart in a baboon
113. Liver-islet transplantation in type 2 diabetes